Anxiety and Depression Perceived by Individuals With and Without Cancer During the COVID-19 Pandemic Period
1 other identifier
observational
1,107
1 country
1
Brief Summary
The COVID-19 pandemic has negatively affected individuals not only physiologically but also psychologically. The aim of this study is to examine the anxiety and depression status of cancer patients, individuals with non-cancer chronic diseases and healthy individuals with an online screening questionnaire during the COVID-19 pandemic period.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started May 2020
Shorter than P25 for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
May 8, 2020
CompletedPrimary Completion
Last participant's last visit for primary outcome
June 25, 2020
CompletedStudy Completion
Last participant's last visit for all outcomes
June 25, 2020
CompletedFirst Submitted
Initial submission to the registry
January 5, 2021
CompletedFirst Posted
Study publicly available on registry
January 6, 2021
CompletedJanuary 7, 2021
January 1, 2021
2 months
January 5, 2021
January 5, 2021
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
HADS
The score of Hospital Anxiety Depression Scale
14 days
Study Arms (3)
Healthy
Have not chronic disease
Cancer
Have cancer
Non-Cancer Crhronic Disease
Have non-cancer chronic disease
Interventions
HADS is a self-report questionnaire designed to screen the symptoms of anxiety and depression in individuals with medical diseases other than psychiatric illnessesHADS is a self-report questionnaire designed to screen the symptoms of anxiety and depression in individuals with medical diseases other than psychiatric illnesses The 4-point Likert type scale, which consists of 14 items, has 2 subscales. Each of the HADS-Anxiety (HADS-A) and HADS-Depression (HADS-D) subscales has 7 items. The score given for each question varies between 0 and 3. A high score indicates a high level of anxiety and depression. The responses given to the questions are given certain scores, and as a result, a score of 0-7 refers to a normal level, 8-10 to a level at the limit and 11 and above to a high level (abnormal level).
Eligibility Criteria
The sample groups were randomly selected from cancer patients, patients with non-cancer chronic diseases and those without any diseases
You may qualify if:
- Cancer patients, patients with non-cancer chronic diseases and those without any diseases
- years or above
- Literate
You may not qualify if:
- Psychiatric diseases (depression, mania, bipolar disorder, psychosis, obsessive-compulsive disorder, etc.)
- Mental retardation
- Dementia
- Alzheimer's disease were excluded.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Sultan Abdülhamid Han Training and Research Hospital
Istanbul, 34660, Turkey (Türkiye)
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- CROSS SECTIONAL
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- M.D.
Study Record Dates
First Submitted
January 5, 2021
First Posted
January 6, 2021
Study Start
May 8, 2020
Primary Completion
June 25, 2020
Study Completion
June 25, 2020
Last Updated
January 7, 2021
Record last verified: 2021-01
Data Sharing
- IPD Sharing
- Will not share